Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma
Not yet recruitingOBSERVATIONAL
Enrollment
400
Participants
Timeline
Start Date
October 30, 2024
Primary Completion Date
May 30, 2025
Study Completion Date
December 30, 2025
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)Double Expressor Lymphoma
All Listed Sponsors
lead
Ruijin Hospital
OTHER
NCT06652152 - Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma | Biotech Hunter | Biotech Hunter